Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)

Trial Profile

A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AADi
  • Most Recent Events

    • 06 Apr 2019 Results (n=6) of preliminary analysis of ABI-009 assessing safety, functional and hemodynamic outcomes, presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 18 Mar 2019 Results (n=6) assessing safety and efficacy of ABI-009 in patients with severe pulmonary arterial hypertension, presented at the 68th Annual Scientific Session of the American College of Cardiology
    • 19 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top